Key facts
- Rebel Medicine’s last known valuation is $9.5M (Dec 2021).
- It has raised $9.1M across 1 recorded rounds; the latest was Early Stage VC ($8.8M) in Feb 2025.
- Notable investors include US National Science Foundation, National Institutes of Health, Altitude Lab, Cantina Angels, Central Texas Angel Network — 11 tracked in total.
- Rebel Medicine has filed 1 Form D with the SEC, most recently Feb 2025 ($6.1M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Rebel Medicine
Funding rounds
1 roundsAbout Rebel Medicine
Operator of a preclinical-stage life sciences company intended for leveraging innovative drug delivery science to transform how therapeutics are delivered. The company's leading program is an injectable, long-acting local anesthetic intended to provide 96-120 hours of safe, effective analgesia after surgery mitigate the need for opioids, and deliver injectable shear-thinning gel suitable for a wide variety of active pharmaceutical ingredients including small molecule and peptide therapies, enabling pharmaceutical companies to focus on improving the effectiveness of existing drugs in order to provide superior pain management solutions at a low cost.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2020
- Employees
- 12
- Website
- rebelmedicine.com/
- Ownership
- Privately Held (backing)
Rebel Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rebel Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rebel Medicine in its N-PORT filings yet. We sweep new filings monthly.